Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Approaches Targeting the FGF–FGFR System: a Review of the Recent Patent Literature and Associated Advanced Therapeutic Agents
Corentin Herbert, Gilbert Lassalle, Chantal Alcouffe, et al.
Pharmaceutical Patent Analyst (2014) Vol. 3, Iss. 6, pp. 585-612
Closed Access | Times Cited: 23

Showing 23 citing articles:

New developments in the biology of fibroblast growth factors
David M. Ornitz, Nobuyuki Itoh
WIREs Mechanisms of Disease (2022) Vol. 14, Iss. 4
Open Access | Times Cited: 98
FGF Family: From Drug Development to Clinical Application
Qi Hui, Zi Jin, Xiaokun Li, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 7, pp. 1875-1875
Open Access | Times Cited: 148
Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives
Alessandro Inno, Giuseppe Bogina, Monica Turazza, et al.
The Oncologist (2015) Vol. 21, Iss. 1, pp. 28-32
Open Access | Times Cited: 126
The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis
Roberto Ronca, Arianna Giacomini, Marco Rusnati, et al.
Expert Opinion on Therapeutic Targets (2015) Vol. 19, Iss. 10, pp. 1361-1377
Closed Access | Times Cited: 82
Blocking the FGF/FGFR system as a ⿿two-compartment⿿ antiangiogenic/antitumor approach in cancer therapy
Arianna Giacomini, Paola Chiodelli, Sara Matarazzo, et al.
Pharmacological Research (2016) Vol. 107, pp. 172-185
Closed Access | Times Cited: 77
The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
Navid Sobhani, Chunmei Fan, Pedro O. Flores-Villanueva, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 2011-2011
Open Access | Times Cited: 55
Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders
Cortney A. Turner, Emine Eren‐Koçak, Edny Gula Inui, et al.
Seminars in Cell and Developmental Biology (2015) Vol. 53, pp. 136-143
Open Access | Times Cited: 61
High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer
Aleksandra Sokołowska-Wędzina, Grzegorz Chodaczek, Julia Chudzian, et al.
Molecular Cancer Research (2017) Vol. 15, Iss. 8, pp. 1040-1050
Open Access | Times Cited: 43
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
Navid Sobhani, Anna Ianza, Alberto D’Angelo, et al.
Cells (2018) Vol. 7, Iss. 7, pp. 76-76
Open Access | Times Cited: 42
Acid fibroblast growth factor preserves blood-brain barrier integrity by activating the PI3K-Akt-Rac1 pathway and inhibiting RhoA following traumatic brain injury.
Fenzan Wu, Zaifeng Chen, Chonghui Tang, et al.
PubMed (2017) Vol. 9, Iss. 3, pp. 910-925
Closed Access | Times Cited: 38
FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1
K. Świderska, Anna Szlachcic, Łukasz Opaliński, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 7, pp. 2098-2098
Open Access | Times Cited: 28
The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor
Rafael Morales‐Barrera, Cristina Suárez, Macarena González, et al.
Cancer Treatment Reviews (2020) Vol. 86, pp. 102000-102000
Closed Access | Times Cited: 26
Nanodiamonds as traps for fibroblast growth factors: Parameters influencing the interaction
Jana Mikešová, Daria Miliaieva, Pavla Štenclová, et al.
Carbon (2022) Vol. 195, pp. 372-386
Closed Access | Times Cited: 13
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor
Yoshito Nakanishi, Hideaki Mizuno, Hitoshi Sase, et al.
Molecular Cancer Therapeutics (2015) Vol. 14, Iss. 12, pp. 2831-2839
Open Access | Times Cited: 24
MiR‐3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway
Shiqi Kong, Yingxiao Cao, Xin Li, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 8, pp. 4677-4686
Open Access | Times Cited: 19
Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping
Yikai Wang, Zhenxia Chen, Meibi Dai, et al.
Bioorganic & Medicinal Chemistry Letters (2017) Vol. 27, Iss. 11, pp. 2420-2423
Closed Access | Times Cited: 18
Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents
Leisl Packer, Pamela M. Pollock
Cancer Discovery (2015) Vol. 5, Iss. 4, pp. 355-357
Open Access | Times Cited: 16
Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry
Burcu Doğan-Topal, Wenlong Li, Alfred H. Schinkel, et al.
Journal of Chromatography B (2019) Vol. 1110-1111, pp. 116-123
Open Access | Times Cited: 10
Towards More Powerful Antibodies for Fibroblast Growth Factor Receptors in Breast Cancer
Navid Sobhani, Chunmei Fan, Pedro O. Flores-Villanueva, et al.
(2020)
Open Access | Times Cited: 1
Design, Synthesis and Biological Evaluation: 5-amino-1H-pyrazole-1- carbonyl derivatives as FGFR Inhibitors
Yan Fei Zhang, N T Yu
Letters in Drug Design & Discovery (2020) Vol. 17, Iss. 11, pp. 1330-1341
Closed Access | Times Cited: 1
Fibroblast Growth Factor Receptor Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors
Cinta Hierro, Josep Tabernero
Elsevier eBooks (2018), pp. 101-121
Closed Access
Neuroendocrine breast tumors: our experiences and a review of the literature
Ezgi Altinsoy, Serdar Çulcu, Ferit Aydın
Acta Oncologica Turcica (2020) Vol. 53, Iss. 1, pp. 117-122
Open Access
Treatment of NETs from Rare Origin
Nazarena Betella, Valeria Smiroldo, Roberto Baldelli, et al.
Springer eBooks (2021), pp. 211-229
Closed Access
Page 1

Scroll to top